Glass House Brands Inc. Subordi (GLAS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- -$0.02
- Estimate
- -$0.06
- Surprise
- +67.5%
- Score today
- 5.3/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Glass House Brands Inc. Subordi (GLAS) reported a narrower loss than forecast — adjusted EPS of -$0.02 against the -$0.06 estimate (a 67.5% beat on a still-unprofitable quarter).
Coverage in the report window
- Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s — benzinga, 2026-08-14
- Glass House Brands Q2 2026 Earnings Call Transcript — benzinga, 2026-08-13
Where TrendMatrix's rating stands now
TrendMatrix currently rates GLAS Sell at 5.3/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +67.5% surprise compares with a +110.3% four-quarter average. Next scheduled report: 2026-11-11.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $16.00 vs price $5.16 — ratio 3.1×). Rejected, falling back to technical TP.
- Quality below floor (1.7 < 4.0)
- Momentum score 2.9/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $5.16
- Price target
- $8.25
- Stop
- $4.82
- Upside to target
- +59.9%
Risk check: RSI 8 — a level conventionally read as oversold; trading volume is running 1.7× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
GLAS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $504.2M
- P/E (fwd)
- 23.8
- 52-week range
- $4.97–$13.93
- Off 52-week high
- 63.0%
- RSI (14)
- 8
- Volume vs avg
- 1.67×
- Score today
- 5.3/10